Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 8:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Novel Influenza A Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01859143
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Trivalent Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 9, 2014 · Synced Sep 22, 2026, 8:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49

NCT01658800
View directory record Official record
Conditions
Influenza
Interventions
VAX161C vaccine
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
South Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 22, 2026, 8:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Prospective Study to Evaluate the Safety of a New Trivalent Intranasal Influenza Vaccine

NCT00677820
View directory record Official record
Conditions
Influenza
Interventions
Trivalent influenza virus vaccine, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Daytona Beach, Florida • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2010 · Synced Sep 22, 2026, 8:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine

NCT00873912
View directory record Official record
Conditions
Healthy
Interventions
Monovalent influenza virus vaccine, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
3
States / cities
Daytona Beach, Florida • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Sep 22, 2026, 8:12 PM EDT
Recruiting Phase 1 Interventional

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

NCT07044544
View directory record Official record
Conditions
Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
G-CSF, Decitabine, Venetoclax
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 22, 2026, 8:12 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)

NCT00972816
View directory record Official record
Conditions
Influenza
Interventions
MF59-eH1N1
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
3 Years to 8 Years
Enrollment
1,357 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
34
States / cities
Downey, California • Madera, California • Paramount, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 22, 2026, 8:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

D2560C00015 FluMist Annual Safety Study 2018

NCT03564444
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Bivalent influenza vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Sep 22, 2026, 8:12 PM EDT
Completed No phase listed Observational

Clinical Characteristics and Outcomes in Patients Diagnosed With Novel Influenza A (H1N1)

NCT01024673
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2021 · Synced Sep 22, 2026, 8:12 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001

NCT01224262
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine), LIQ001 (0.45mg), LIQ001 (1.8mg)
Biological
Lead sponsor
Liquidia Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Sep 22, 2026, 8:12 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)

NCT07159763
View directory record Official record
Conditions
Influenza
Interventions
MK-1406, Placebo
Combination Product
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
12 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
240
States / cities
Anniston, Alabama • Cullman, Alabama • Glendale, Arizona + 109 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 22, 2026, 8:12 PM EDT
Completed No phase listed Observational

Novel Influenza A (H1N1) Surveillance Registry

NCT01046331
View directory record Official record
Conditions
Novel Influenza A, H1N1, Influenza
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
86
States / cities
Anchorage, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 22, 2026, 8:12 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)

NCT07225959
View directory record Official record
Conditions
Healthy Participants
Interventions
MK-1406 Injection
Combination Product
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 66 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
4
States / cities
Miami Lakes, Florida • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 22, 2026, 8:12 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)

NCT07300085
View directory record Official record
Conditions
Healthy Participants
Interventions
Fluzone® High-Dose (HD) influenza vaccine, MK-1406 Injection, Placebo
Biological · Combination Product
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 49 Years
Enrollment
710 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 22, 2026, 8:12 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults

NCT00125944
View directory record Official record
Conditions
Healthy, Influenza
Interventions
FluMist
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
4
States / cities
San Diego, California • Daytona Beach, Florida • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2007 · Synced Sep 22, 2026, 8:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults

NCT01172054
View directory record Official record
Conditions
Influenza
Interventions
VAX128, Placebo
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Sep 22, 2026, 8:12 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Influenza Vaccine as a Novel Experimental Model of the Behavioral Immune Response in Depression

NCT03756246
View directory record Official record
Conditions
Depression, Healthy
Interventions
Influenza Vaccine
Biological
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Sep 22, 2026, 8:12 PM EDT
Completed Not applicable Interventional

Efficacy Study of School-located Influenza Vaccination Clinics to Increase Influenza Vaccination Rates in Monroe County, New York

NCT02227186
View directory record Official record
Conditions
Childhood Influenza Vaccination, School-located Influenza Vaccination
Interventions
School-located Influenza Vaccination Clinic
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
4 Years to 19 Years
Enrollment
20,461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2017 · Synced Sep 22, 2026, 8:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01579916
View directory record Official record
Conditions
Influenza
Interventions
Trivalent Influenza Virus Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 2, 2014 · Synced Sep 22, 2026, 8:12 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)

NCT05275686
View directory record Official record
Conditions
Eustachian Tube Dysfunction
Interventions
Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray, Placebo Nasal Spray
Drug · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Sacramento, California • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 22, 2026, 8:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults

NCT07019883
View directory record Official record
Conditions
Avian Influenza
Interventions
H5 AC-Anhui RNA Vaccine, H5 Astrakhan RNA Vaccine, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Durham, North Carolina • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 22, 2026, 8:12 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season

NCT02473510
View directory record Official record
Conditions
Influenza, Healthy
Interventions
Trivalent Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
South Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 27, 2016 · Synced Sep 22, 2026, 8:12 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children

NCT02207413
View directory record Official record
Conditions
Influenza
Interventions
Influsplit Tetra™ vaccine produced by investigational process (IP), Influsplit Tetra™ vaccine produced by licensed process (LP)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 49 Years
Enrollment
1,886 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
4
States / cities
Wichita, Kansas • Rochester, New York • Warwick, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 22, 2026, 8:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.

NCT01855945
View directory record Official record
Conditions
Prophylaxis of A/H3N2v Influenza
Interventions
Swine Influenza
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
3 Years to 92 Years
Enrollment
627 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
11
States / cities
Redding, California • Sacramento, California • Lenexa, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 22, 2026, 8:12 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)

NCT00240877
View directory record Official record
Conditions
Influenza
Interventions
AV024, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 19, 2008 · Synced Sep 22, 2026, 8:12 PM EDT